How did Madrigal Pharmaceuticals Inc perform in its last earnings report?

On 2026-11-03, Madrigal Pharmaceuticals Inc reported EPS of 1.90 and +315.41% EPS surprise. Revenue was 431.27M, compared with the consensus estimate of 404.26M.

What does an earnings surprise mean?

An earnings surprise is the difference between a company's reported EPS or revenue and the analysts' consensus estimate. A positive surprise means results exceeded expectations, while a negative surprise means results fell short.

How can earnings reports affect MDGL stock?

Earnings reports can increase volatility in MDGL stock, especially when reported EPS, revenue or company guidance differs from market expectations. An earnings beat does not always lead to a price increase, as investors also consider the outlook, valuation and broader market conditions.

Madrigal Pharmaceuticals Inc Earnings Dates & Reports

This page offers detailed Madrigal Pharmaceuticals Inc earnings data including the latest Madrigal Pharmaceuticals Inc earnings report, the upcoming Madrigal Pharmaceuticals Inc earnings date, historical data and Madrigal Pharmaceuticals Inc earnings call news.

MDGL Latest Quarter’s Earnings

Announce Date11/3/2026

EPS Actual (USD)1.90

Revenue Actual (USD)431.27M

MDGL Upcoming Quarter's Earnings

Announce Date--

EPS Forecast (USD)--

Revenue Forecast (USD)--

MDGL FY2025 Earnings

EPS (YoY)-12.8541.33%

Revenue (YoY)958.40M432.05%

Madrigal Pharmaceuticals Inc (MDGL) Earnings History

Release Date	Period End	EPS/Forecast	Revenue/Forecast	EPS Surprise %	Revenue Surprise %
11/3/2026	09/2026	1.90/-0.88	431.27M/404.26M	315.96%	6.68%
7/30/2026	06/2026	-1.99/-2.57	364.25M/353.18M	22.52%	3.14%
5/6/2026	03/2026	-3.25/-4.03	311.34M/300.76M	19.31%	3.52%
2/19/2026	12/2025	-2.55/-0.67	321.08M/312.49M	-278.82%	2.75%
11/4/2025	09/2025	-5.08/-2.08	287.27M/247.31M	-144.00%	16.16%
8/5/2025	06/2025	-1.90/-3.64	212.80M/162.32M	47.65%	31.10%
5/1/2025	03/2025	-3.32/-3.76	137.25M/113.82M	11.85%	20.59%
2/26/2025	12/2024	--/--	103.32M/98.56M	--	4.83%

Madrigal Pharmaceuticals Inc Latest Earnings Call Transcripts

Madrigal Pharmaceuticals (MDGL) Q3 2026 Earnings Call: Rezdiffra Sales Rise 50%

Madrigal Pharmaceuticals Q3 2026 earnings call: Rezdiffra sales rose 50% to $431.3 million, active patients topped 55,800, and net income reached $55.4 million.